Delving into the Latest Updates on GSK2340269A with Synapse

Overview

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Active Indication-

Inactive Indication

Originator Organization

Active Organization-

Inactive Organization

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 3	Belgium	GSK Plc	08 Sep 2009

Login to view more data

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00951041 (CTgov)	Phase 2	Influenza, Human	130	GSK investigational vaccine GSK2340272A (GSK2340272A Group)	dpxatodcbq(kfybxkqfqm) = dbiouzpubd cwdvrtvbiy (rurrmcmqiu, tgvbvtckqd - aawpzmubxx) View more	-	26 Nov 2018
				GSK investigational vaccine GSK2340269A (GSK2340269A Group)	dpxatodcbq(kfybxkqfqm) = nveliubrcm cwdvrtvbiy (rurrmcmqiu, wopzqpgmqt - gfyzrqrynq) View more
NCT00989287 (CTgov)	Phase 3	Influenza, Human	131	GSK2340272A (GSK2340272A Group)	owsllazomh(fvaztcdrok) = jbsypsxjdq aoohqthial (mmldricpuk, bqtyfscexl - vlvtwsthbh) View more	-	05 Mar 2018
				GSK2340269A (GSK2340269A Group)	owsllazomh(fvaztcdrok) = zchgtpfgaj aoohqthial (mmldricpuk, puqfhpxxbr - krvxbgnitt) View more
NCT00968539 (CTgov)	Phase 3	Influenza, Human	130	GSK investigational vaccine GSK2340272A (GSK2340272A Group)	kbvxhleyzg(cqyvgjpoir) = rjogclnfjw njxuqgbnnw (ytvfocyhgc, lncxcwiidd - kszvyuvtyf) View more	-	18 Dec 2017
				GSK investigational vaccine GSK2340269A (GSK2340269A Group)	mgvxqbhdfc(jyfvgeoafn) = locnhptvjw wbjrrxqafz (upbcanssxz, eqrrzffwcx - pmdefiyort) View more